Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Exelixis CEO Michael Morrissey reported strong commercial growth for cabozantinib, with revenue projected to surpass $2.1 billion this year, driven by demand in RCC and a successful initial launch in neuroendocrine tumors (NETs), supporting an aspirational $3 billion peak by 2030. The company also announced positive top-line results for zanzalintinib's STELLAR-303 trial in late-line colorectal cancer, with regulatory filing discussions ongoing, positioning zanza as a future $5 billion peak asset and a key element in the planned transition from cabozantinib. Exelixis continues to advance a deep oncology pipeline, including XB371 and XL309, while maintaining approximately $1 billion in annual R&D spend and executing share repurchases to build long-term shareholder value and mitigate future patent cliffs.

Analysis

Exelixis is demonstrating strong commercial execution with its primary value driver, cabozantinib, which is on track to exceed $2.1 billion in revenue this year, up from $1.8 billion last year. This growth is primarily demand-driven, highlighted by a 19% year-over-year revenue increase in Q2, an 18% rise in demand, and a steady gain of approximately one percentage point of market share per quarter in frontline Renal Cell Carcinoma (RCC). The recent launch in neuroendocrine tumors (NET) has had a robust start, capturing a 35% market share and contributing roughly $20 million in its first full quarter, reinforcing the company's aspirational $3 billion peak sales target for the cabozantinib franchise. Concurrently, the company is actively de-risking its future pipeline with zanzalintinib, which achieved positive top-line results in the STELLAR-303 trial for late-line colorectal cancer (CRC). This win in the broad intent-to-treat (ITT) population is particularly significant given recent failures by competitors in this setting and positions zanzalintinib as a potential $5 billion peak sales asset. The overarching strategy is to orchestrate a smooth transition from cabozantinib to zanzalintinib before the former's patent expiration around 2030, aiming to mitigate the patent cliff. This is supported by a disciplined capital allocation strategy, including a ~$1 billion annual R&D budget and a significant share repurchase program that has returned $1.8 billion to shareholders over the past two years.

Key Decisions for Investors

• Investors should monitor cabozantinib's quarterly performance, particularly the growth trajectory in RCC and the adoption ramp in the new NET indication, as this execution is the primary source of cash flow funding the pipeline and buybacks.
• The positive top-line data for zanzalintinib in CRC is a critical de-risking event; upcoming catalysts to watch for are the full data presentation and the subsequent regulatory filing, which will be key in validating the drug's multi-billion dollar potential.
• The core long-term thesis rests on managing the 2030-2031 patent cliff, therefore progress on zanzalintinib's other pivotal trials, especially in kidney cancer, should be scrutinized to assess its ability to become the new standard of care.
• Consider the company's disciplined capital allocation, including the ~$1 billion R&D cap and consistent share repurchases, as a positive signal for P&L management and shareholder returns, which provides a degree of valuation support.